TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: onset of pain relief
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: maximal block height
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: time to maximal block
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: decreased meconium concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: rate of meconium aspiration syndrome
Endpoint domain: Adverse events/effects
Primary endpoint: Mean ODI change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bone fusion rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bromage score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: plasma GLP-1 concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: plasma PYY concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: appetite ratings
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: median ventilator days
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean quasi-American Urological Association Symptom Score improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Median prostate volume decrease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Urological outcomes
Primary endpoint: Mean maximal urinary flow rate increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: Urological outcomes
Primary endpoint: Death or (re)infarction at 30 days
Endpoint domain: Mortality/survival
Primary endpoint: Death or (re)infarction at 6 months
Endpoint domain: Mortality/survival
Primary endpoint: serum sodium levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: NT-proBNP reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: MADRS total score improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: rapid eradication
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: rebleeding
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Seroprevalence rates of measles, mumps, and rubella
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Provider-patient rapport
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Proportion of patients with controlled blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: total jet lag score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of dose detected in the aqueous humor
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: sleep measures
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Complete tumor necrosis rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Negative conversion rate of AFP positivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: gallbladder volume reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: number of documented bacteremic events
Endpoint domain: Adverse events/effects
Primary endpoint: Family Received Index
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Family End-of-study Up-to-date indices
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: central line‐associated bloodstream infection rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: frequency of dressing changes
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: 30-day alcohol use
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: heavy episodic drinking
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Complete ovarian suppression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Rates of adverse events (AEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Rates of serious adverse events (SAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Weight gain of infants
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Motor responses in infants
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in lesion erythema
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Improvement in overall skin condition
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Alcohol and illicit drug use
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma concentrations of 17-BMP
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC0-t and Cmax for 17-BMP
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: sweat chloride
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: duration of cough
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: duration of rhinorrhoea
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: frequency of having two or more symptoms of the common cold
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CD45 ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: CD16/56 ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: aggressive behaviour
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: diameter stenosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: late loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: relapse of depression
Endpoint domain: Mortality/survival
Primary endpoint: Weight measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: BMI measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Complete recanalization rates at 24 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Early clinical improvement (NIHSS change)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Favorable 90-day outcomes (mRS 0-1)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: 3-year mortality
Endpoint domain: Mortality/survival
Primary endpoint: reduction of left ventricular mass
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Improvement in visual acuity (VA) of the amblyopic eye
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean prosthesis size improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: effective valve opening area
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: overall success rate
Endpoint domain: Mortality/survival
Primary endpoint: ongoing pregnancy rate
Endpoint domain: Mortality/survival
Primary endpoint: incidence of diarrhoea
Endpoint domain: Adverse events/effects
Primary endpoint: Reduction in pro-inflammatory cytokines
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Serum D3 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the curve for serum D3
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in weekly episodes of faecal incontinence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Lidocaine clearance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC for initial 6 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Tmax following injection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Mean IGFBP-3 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: neuromuscular control
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: coordination
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline HAM-D 17 score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Major cardiovascular event
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Cardiac event
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Cerebrovascular event
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Time to return to daily activities or work
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Psychological dependence
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Primary cardiac end point
Endpoint domain: Mortality/survival
Primary endpoint: maximum percentage fall in forced expiratory volume in one second (FEV1)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Maintaining an eGFR >60 ml min-1 1.73 m-2
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Improving KDIGO risk category
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: hematocrit levels in irrigation fluid
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: mean tumour size
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: surgical cure rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Subjective intoxication
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postdrinking BAC
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: TRT consumption
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: improvements in lung function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: reduced risk of severe exacerbation
Endpoint domain: Adverse events/effects
Primary endpoint: HIV viral load
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: disease progression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Medication Possession Ratio (MPR) above 80%
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: performance on a terminology test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mental effort during testing
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Overall treatment satisfaction
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: number of hypoglycemic events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Mean time until eye opening
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time spent in recovery room
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: clinical performance improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction of social anxiety symptoms
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Functional Improvement (FM increase)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: day‐3 embryo scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: implantation rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Correct technique demonstration skills
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of metabolic syndrome
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: nausea severity in the acute phase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: nausea severity in the delayed phase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: smoking abstinence rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quality of participation
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Quantity of participation
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Increase in HDL cholesterol
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Decrease in total cholesterol: HDL ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Diastolic function improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: flow‐mediated vasodilation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: hs‐CRP levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: prevalence of the metabolic syndrome
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: gain in fat mass (arm)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: gain in fat mass (leg)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to Progression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Progression-Free Survival
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Severity of MEB grades
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Measurement of OzVal-Hb biomarker
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Incident hypertension
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Complete ablation of IM and HGD
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: World Health Organization functional class
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: clinical worsening-free survival
Endpoint domain: Mortality/survival
Primary endpoint: IL-4 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: IgE levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Stroke rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Myocardial infarction rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: access site-related complications
Endpoint domain: Adverse events/effects
Primary endpoint: Complete periapical healing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Correlation between bioimpedance monitor and thermodilution-derived cardiac output
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Progression-free survival at 6 months
Endpoint domain: Mortality/survival
Primary endpoint: Incidence of primary graft dysfunction >1
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Neonatal heart rate changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Influenza attack rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Vein graft patency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Creatinine increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Recurrence of atrial tachycardia (AT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in GERD symptom scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of patients with lower PGA scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Basal plasma astaxanthin concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Effectiveness of LMWH vs UFH
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diagnostic acceptability of protocols
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Contrast enhancement peak time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean diurnal IOP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Proportion of patients achieving target diurnal IOP <17 mm Hg
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Number of non-responders
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Degree of exophthalmos
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean individual reviewer rating change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in spherical equivalent refraction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Short physical performance battery chair stand test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Radiological success rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PTT (Pain Threshold Time)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: VAS (Visual Analog Scale) scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Multiple-organ-dysfunction-free days
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Respiratory-failure-free days
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: SIT improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean observer confidence scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ridge width change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ridge height change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bone quantity observed
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reported physical activity levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Day-10 surrogate Hospital Anxiety and Depression Scale score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: patient unresponsiveness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of patients with visible oesophageal inlet
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of TOE probe insertion attempts
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of pharyngeal mucosal injury
Endpoint domain: Adverse events/effects
Primary endpoint: Rate of occlusion per 1000 catheter days
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HRQOL improvements on scales measuring physical activity
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: HRQOL improvements on SF‐36 Vitality Subscale Score
Endpoint domain: Life impact
Endpoint subdomain: Vitality
Primary endpoint: HRQOL improvements on FACT fatigue scale
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Mean cold duration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PLM index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: time in bed without movements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 15-year biochemical or clinical failure
Endpoint domain: Mortality/survival
Primary endpoint: 15-year cumulative incidence of distant metastasis
Endpoint domain: Mortality/survival
Primary endpoint: 15-year cumulative incidence of prostate cancer-specific mortality
Endpoint domain: Mortality/survival
Primary endpoint: 24-hour postoperative pain score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 7-day postoperative cosmetic satisfaction score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Dental utilization
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Height at mean age of 23.5 years
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Age of peak height velocity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Amniotic Fluid Index (AFI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Urinary Specific Gravity (USG) change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frusemide excretion rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes